Q-omics provides the consensus-scored RPL23P8 profile across patient tissues and cancer cell-line models. RPL23P8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL23P8 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RPL23P8 RNA expression shows 13,083 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight OV, COAD, and DLBC as cancer lineages where RPL23P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23P8 survival associations across molecular data types. RPL23P8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23P8 RNA expression–survival associations across cancer types. High RPL23P8 expression shows unfavorable associations in OV, LIHC, ACC and PAAD, but favorable associations in CESC and THCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for RPL23P8 RNA expression.
This table summarizes RPL23P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23P8 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRC, LIHC, CHOL and KIRP. The COAD box plot shows higher RPL23P8 RNA expression in tumor versus normal tissue (log2 FC = +0.984, t-test p < 0.001).
This table shows molecular features associated with RPL23P8 in patient tissues and cancer cell lines. In patient samples, RPL23P8 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
